Ticker LaunchSPAC · Liquidated
Eucrates Biomedical Acquisition Corp.
Eucrates Biomedical Acquisition Corp. is a blank-check company (SPAC) that raised $100M in its initial public offering on Oct 26, 2020, listing on Nasdaq Capital Market. It did not complete a business combination and liquidated around Apr 26, 2023, returning the trust to public shareholders. J.P. Morgan led the IPO, with Goldman Sachs and Citigroup. Proskauer Rose advised the SPAC and Kirkland & Ellis advised the underwriters on the IPO.
- Status
- Liquidated
- IPO date
- Oct 26, 2020
- IPO size
- $100M
- IPO exchange
- Nasdaq Capital Market
- IPO underwriters
- J.P. Morgan, Goldman Sachs and Citigroup
- SPAC counsel (IPO)
- Proskauer Rose and Ogier
- Underwriters' counsel (IPO)
- Kirkland & Ellis
More on this SPAC for subscribers
- Trust balance and value per share
- Liquidation deadline and extension history
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- IPO prospectus (424B4) Oct 26, 2020
- All filings on EDGAR CIK 1822929
Other SPAC IPOs from 2020
- Lux Health Tech Acquisition Corp.Oct 28, 2020 · $300M
- Ajax IOct 28, 2020 · $750M
- Mallard Acquisition Corp.Oct 27, 2020 · $110M
- Acies Acquisition Corp.Oct 26, 2020 · $200M
- DPCM Capital, Inc.Oct 23, 2020 · $300M
- BCLS Acquisition Corp.Oct 23, 2020 · $125M